SciSparc Ltd. Announces Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc.
June 07 2022 - 8:30AM
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage
pharmaceutical company focusing on the development of therapies to
treat disorders of the central nervous system (the "Company" or
"SciSparc"), today announced that initial positive pre-clinical
results for treatment for cocaine addiction using MEAI, a novel
psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE:
CMND), (OTC: CMNDF), (FSE: CWY0).
Pursuant to SciSparc last announcement on June
2, 2022, whereby the Company announced the collaborated filing of a
provisional patent application related to treating cocaine
addiction with Clearmind based on SciSparc’s CannAmide™ compound
and Clearmind’s MEAI, the pre-clinical trials show possible
positive results which may positively affect our collaboration.
"We are excited about Clearmind's results, in light of the
potential synergistic effect between SciSparc’s CannAmide compound
and Clearmind’s MEAI, as previously demonstrated in joint studies,
which reflected the dose dependency effect. We plan to continue to
investigate these findings, which for the first time point to a
potential treatment for cocaine addiction. Since commencing the
collaboration with Clearmind, we have been able to present
successful results for our proprietary combination treatment”
commented Oz Adler, SciSparc's Chief Executive Officer. "It is our
intention to further investigate the effect of this treatment on
different addictions and other binge behaviors".
The pre-clinical trial was led by Professor Gal
Yadid and his team from the Gonda Multidisciplinary Brain Research
Center located at Bar Ilan University (Ramat Gan, Israel) and was
designed to evaluate the possible reward-like effects of MEAI. Four
different doses of MEAI were compared to cocaine in the conditioned
place preference (CPP) model in male Sprague-Dawley rats. Rats
received either MEAI or cocaine. Based on statistically significant
reductions in the reward effect as compared to cocaine, it was
determined that MEAI is not rewarding. Additionally, some rats that
received cocaine were treated with MEAI on the test day to
determine if MEAI has a treatment-like effect. Rats were
conditioned with cocaine and on the day of the test were treated
with MEAI. The results obtained suggest MEAI’s ability to abolish
cocaine induced conditioned place preference. The results of this
ground-breaking research show potential for the first dedicated
cocaine addiction treatment.
About SciSparc Ltd. (NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. SciSparc’s focus is on creating and
enhancing a portfolio of technologies and assets based on
cannabinoid pharmaceuticals. With this focus, the Company is
currently engaged in the following drug development programs based
on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the
treatment of Tourette syndrome and for the treatment of Alzheimer's
disease and agitation; SCI-160 for the treatment of pain; and
SCI-210 for the treatment of autism spectrum disorder and status
epilepticus.
About Clearmind Inc. (CSE: CMND), (OTC: CMNDF),
(FSE: CWY0)
Clearmind is a new biotech company focused on
the discovery and development of safe and novel psychedelic-derived
therapeutics to treat alcohol use disorder and other pressing
health challenges.
The Israeli-Canadian company holds several
patents for the non-hallucinogenic compound MEAI
(5-methoxy-2-aminoindane, a novel psychoactive substance). The
company intends to seek additional patents for its compounds
whenever warranted and will remain opportunistic regarding the
acquisition of additional intellectual property to build its
portfolio.
Clearmind has established a research
collaboration with the Hebrew University of Jerusalem and Bar Ilan
University. The partnerships aim to expand its R&D capabilities
and discover new candidate treatments for other mental health
issues.
Forward-Looking Statements:
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. For example, SciSparc is using
forward-looking statements when it discusses the potential benefits
of CannAmide™ and MEAI for treating cocaine abuse and the intention
of SciSparc to further investigate the effect of CannAmide with
MEAI on different addictions and other binge behaviors. Historic
results of scientific research and clinical and preclinical trials
do not guarantee that the conclusions of future research or trials
will suggest identical or even similar conclusions. Because such
statements deal with future events and are based on SciSparc's
current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements of
SciSparc could differ materially from those described in or implied
by the statements in this press release. The forward-looking
statements contained or implied in this press release are subject
to other risks and uncertainties, including those discussed under
the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F
filed with the U.S. Securities and Exchange Commission (“SEC”)
on April 28, 2022, and in subsequent filings with the SEC.
Except as otherwise required by law, SciSparc disclaims any
intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or
otherwise.
Investor Contact: IR@scisparc.com Tel:
+972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Apr 2023 to Apr 2024